PL2007885T3 - Sposób zwiększania odzysku peptydów terapeutycznych in vivo - Google Patents
Sposób zwiększania odzysku peptydów terapeutycznych in vivoInfo
- Publication number
- PL2007885T3 PL2007885T3 PL07723889T PL07723889T PL2007885T3 PL 2007885 T3 PL2007885 T3 PL 2007885T3 PL 07723889 T PL07723889 T PL 07723889T PL 07723889 T PL07723889 T PL 07723889T PL 2007885 T3 PL2007885 T3 PL 2007885T3
- Authority
- PL
- Poland
- Prior art keywords
- therapeutic polypeptides
- increasing
- vivo recovery
- polypeptides
- recovery
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 238000011084 recovery Methods 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 238000001727 in vivo Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06007552 | 2006-04-11 | ||
| PCT/EP2007/002948 WO2007115724A2 (en) | 2006-04-11 | 2007-04-02 | Method of increasing the in vivo recovery of therapeutic polypeptides |
| EP07723889A EP2007885B1 (en) | 2006-04-11 | 2007-04-02 | Method of increasing the in vivo recovery of therapeutic polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2007885T3 true PL2007885T3 (pl) | 2010-12-31 |
Family
ID=36778259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07723889T PL2007885T3 (pl) | 2006-04-11 | 2007-04-02 | Sposób zwiększania odzysku peptydów terapeutycznych in vivo |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20100222554A1 (pl) |
| EP (2) | EP2263696A1 (pl) |
| JP (1) | JP2009533364A (pl) |
| KR (1) | KR101492422B1 (pl) |
| AT (1) | ATE474917T1 (pl) |
| AU (1) | AU2007236280B2 (pl) |
| CA (1) | CA2649199C (pl) |
| DE (1) | DE602007007923D1 (pl) |
| DK (1) | DK2007885T3 (pl) |
| ES (1) | ES2349024T3 (pl) |
| PL (1) | PL2007885T3 (pl) |
| WO (1) | WO2007115724A2 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| KR101542752B1 (ko) | 2006-12-22 | 2015-08-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 변형된 응고 인자 |
| US20110154516A1 (en) * | 2007-10-15 | 2011-06-23 | Stafford Darrel W | Human factor ix variants with an extended half life |
| AU2010284977A1 (en) * | 2009-08-20 | 2012-03-29 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| NZ605348A (en) | 2010-07-09 | 2015-01-30 | Biogen Idec Hemophilia Inc | Factor ix polypeptides and methods of use thereof |
| SI2643468T1 (sl) * | 2010-11-22 | 2018-10-30 | Amicus Therapeutics, Inc. | Nova signalna zaporedja, za izboljšanje izražanje proteinov in izločanje rekombinantnih encimov in drugih proteinov |
| TWI810729B (zh) | 2012-09-25 | 2023-08-01 | 美商百歐維拉提夫治療公司 | Ｆｉｘ多肽的應用 |
| WO2014144549A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor ix polypeptide formulations |
| AR116624A1 (es) | 2018-10-10 | 2021-05-26 | Amicus Therapeutics Inc | Composiciones de polipéptidos estabilizados por enlaces disulfuro y métodos de uso |
| JP2022505876A (ja) * | 2018-10-26 | 2022-01-14 | フリーイェ・ユニヴェルシテイト・ブリュッセル | 遺伝子治療を向上させる新しいツール及びその使用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5364771A (en) * | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| JPH11501506A (ja) * | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
| DE19538715A1 (de) | 1995-10-18 | 1997-04-30 | Behringwerke Ag | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII |
| JP3735921B2 (ja) * | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | ＧＰＩｂ・脂質複合体およびその用途 |
| US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| WO1999066054A2 (en) * | 1998-06-15 | 1999-12-23 | Genzyme Transgenics Corp. | Erythropoietin analog-human serum albumin fusion protein |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| PL206148B1 (pl) * | 2000-02-11 | 2010-07-30 | Bayer HealthCare LLCBayer HealthCare LLC | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
| EP2275557A1 (en) * | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| IL154879A0 (en) * | 2000-10-02 | 2003-10-31 | Novo Nordisk As | Factor vii glycoforms |
| KR20030060915A (ko) * | 2000-10-18 | 2003-07-16 | 맥시겐 에이피에스 | 단백질 씨 또는 활성 단백질 씨-유사 분자 |
| EP1444986A1 (en) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| MXPA06012676A (es) * | 2004-05-04 | 2007-04-02 | Novo Nordisk Healthcare Ag | Glucoformas o-enlazadas de polipeptidos y metodos de fabricacion de los mismos. |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| KR101542752B1 (ko) * | 2006-12-22 | 2015-08-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 변형된 응고 인자 |
-
2007
- 2007-04-02 PL PL07723889T patent/PL2007885T3/pl unknown
- 2007-04-02 US US12/226,188 patent/US20100222554A1/en not_active Abandoned
- 2007-04-02 DE DE602007007923T patent/DE602007007923D1/de active Active
- 2007-04-02 AU AU2007236280A patent/AU2007236280B2/en not_active Ceased
- 2007-04-02 JP JP2009504607A patent/JP2009533364A/ja active Pending
- 2007-04-02 ES ES07723889T patent/ES2349024T3/es active Active
- 2007-04-02 CA CA2649199A patent/CA2649199C/en not_active Expired - Fee Related
- 2007-04-02 EP EP10168156A patent/EP2263696A1/en not_active Withdrawn
- 2007-04-02 KR KR20087027542A patent/KR101492422B1/ko not_active Expired - Fee Related
- 2007-04-02 AT AT07723889T patent/ATE474917T1/de active
- 2007-04-02 WO PCT/EP2007/002948 patent/WO2007115724A2/en not_active Ceased
- 2007-04-02 EP EP07723889A patent/EP2007885B1/en not_active Not-in-force
- 2007-04-02 DK DK07723889.7T patent/DK2007885T3/da active
-
2013
- 2013-06-19 US US13/921,815 patent/US20130337532A1/en not_active Abandoned
-
2014
- 2014-03-27 US US14/227,397 patent/US20140248686A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130337532A1 (en) | 2013-12-19 |
| KR20090008329A (ko) | 2009-01-21 |
| US20100222554A1 (en) | 2010-09-02 |
| CA2649199A1 (en) | 2007-10-18 |
| AU2007236280A1 (en) | 2007-10-18 |
| EP2007885A2 (en) | 2008-12-31 |
| KR101492422B1 (ko) | 2015-02-12 |
| WO2007115724A3 (en) | 2008-03-20 |
| ES2349024T3 (es) | 2010-12-21 |
| EP2007885B1 (en) | 2010-07-21 |
| DK2007885T3 (da) | 2010-11-08 |
| CA2649199C (en) | 2015-01-20 |
| US20140248686A1 (en) | 2014-09-04 |
| AU2007236280B2 (en) | 2013-07-25 |
| ATE474917T1 (de) | 2010-08-15 |
| JP2009533364A (ja) | 2009-09-17 |
| DE602007007923D1 (de) | 2010-09-02 |
| EP2263696A1 (en) | 2010-12-22 |
| WO2007115724A2 (en) | 2007-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2007885T3 (pl) | Sposób zwiększania odzysku peptydów terapeutycznych in vivo | |
| MX2008002101A (es) | Fusiones de la proteina-1 quimiotactica de monocito. | |
| CL2009001258A1 (es) | Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina. | |
| GT200700059A (es) | Proteinas de fusion de exendina | |
| NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
| MX2009007290A (es) | Compuestos agonistas del receptor de la proteina 1 similar al glucagon. | |
| SG171670A1 (en) | Rage fusion proteins, formulations, and methods of use thereof | |
| WO2011008260A3 (en) | Bifunctional stapled polypeptides and uses thereof | |
| WO2008114149A3 (en) | Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains | |
| WO2008085543A8 (en) | Multimeric elp fusion constructs | |
| SG162687A1 (en) | Caustic stable chromatography ligands | |
| JOP20190083A1 (ar) | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها | |
| UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
| MX389347B (es) | Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos. | |
| MX2014000054A (es) | Moleculas de union anti-alfa sinucleina. | |
| EP1945259A4 (en) | FUSION PROTEINS FOR DELIVERY ABOUT THE BLOOD BRAIN BARRIER | |
| NZ584825A (en) | Modified insulin polypeptides and their uses | |
| IL210175A0 (en) | Fn14/trail fusion proteins | |
| EA201170879A1 (ru) | Полипептиды с ксиланазной активностью | |
| WO2010023670A3 (en) | Methods for covalently attaching a polymer to a methionine residue in proteins and peptides | |
| MY149128A (en) | A method for the mass production of immunoglobulin fc region deleted initial methionine residues | |
| WO2014057436A3 (en) | Anticancer conjugate | |
| ATE527345T1 (de) | Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten | |
| WO2009025300A1 (ja) | イミュノグロブリン結合能を有するペプチド | |
| WO2007064727A3 (en) | Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases |